- BiondVax Pharmaceuticals Ltd. (BVXV): Important & Key Factors of Healthcare Stock
- What's the Analyst Recommendation for iHeartMedia Inc. (IHRT)?
- Let’s Take a Look at Milestone Pharmaceuticals Inc. (MIST) Stock
- Is it Time to Sell/Buy United States Steel Corporation (X) Stock After Recent Trade?
- Aptose Biosciences Inc. (APTO) is down -10.05% this year
CLSA announced it was Downgrade coverage of Dr. Reddy’s Laboratories Limited in a research note on January 28, 2020. The analysts assigned an Outperform rating to the stock. CLSA rated the stock as an Outperform in a research noted published on January 27, 2020. Citigroup rated the stock as a Buy in a research note published on January 09, 2020.
RDY Recent Trade
The share price of RDY ascended by $0.12 during the exchanging session on 07/10/20 to exchange at $52.01. Dr. Reddy’s Laboratories Limited stock has an exchanging volume of 0.15 million shares, which is low, contrasted with its 3-months average volume of 216.89K shares. Its market capitalization has now reached to $8.62B and analysts have a consensus target price of $42.25 in the 12-month period.
RDY Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, RDY price has dropped by -1.65%. In the course of past three months sees the stock go up around 10.97%, while it has gain 26.12% over the past six months and 28.17% since the start of the year.
RDY Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Jun 2020), the firm recorded a revenue of 44.32 billion. For that equivalent quarter, Dr. Reddy’s Laboratories Limited posted $0.61 earnings per share (EPS) which was above the consensus estimate of $0.49 by $0.12, which represents to an expansion by 24.50%.
RDY Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Dr. Reddy’s Laboratories Limited has seen its stock exchanging -5.76% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +8.13% above its three-month low. A more extensive look sees RDY exchanging -5.76% beneath its 52-week high and 56.05% above from its 52-week low price.
RDY Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 1.64%, while it has a month to month instability of 1.99%. The company has an ATR (Average True Range) of 1.19 and a beta factor of 0.47.